Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1994-4-26
|
pubmed:abstractText |
The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome affects between 2% and 5% of hirsute women and is characterized by INS resistance, elevated INS levels, acanthosis nigricans, and androgen excess. These patients' response to therapy is unclear, although long-acting GnRH-a suppression has been proposed. The objective of this study was to determine the success of OC in suppressing the hyperandrogenemia of five patients with the hyperandrogenic-insulin-resistant acanthosis nigricans syndrome and the subsequent response to GnRH-a suppression of those women failing initial therapy. After 6 months of OC and SPA therapy, four patients experienced adequate suppression of free T, an increase in SHBG levels, and a subjective improvement in hair growth rate. Two also reported an improvement in hair texture. The total and free T levels in the fifth patient did not suppress after 8 months of OC therapy. Nevertheless, in this patient the administration of a GnRH-a along with hormonal replacement and SPA adequately suppressed free and total T, increased SHBG, and dramatically decreased the shaving interval. In conclusion, although GnRH-a suppression and hormonal replacement can be helpful in patients not responding to standard therapy, the majority of patients with the hyperandrogenic-insulin-resistant acanthosis nigricans syndrome will respond favorably to OC treatment. It is also clear that although hyperinsulinemia augments LH-stimulated androgen biosynthesis in vivo, it does not appear to be able to initiate or maintain androgen production in the absence of adequate gonadotropin stimulation.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0015-0282
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
61
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
570-2
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:8137990-Acanthosis Nigricans,
pubmed-meshheading:8137990-Adolescent,
pubmed-meshheading:8137990-Contraceptives, Oral,
pubmed-meshheading:8137990-Drug Therapy, Combination,
pubmed-meshheading:8137990-Female,
pubmed-meshheading:8137990-Humans,
pubmed-meshheading:8137990-Hyperandrogenism,
pubmed-meshheading:8137990-Insulin Resistance,
pubmed-meshheading:8137990-Leuprolide,
pubmed-meshheading:8137990-Medroxyprogesterone Acetate,
pubmed-meshheading:8137990-Spironolactone
|
pubmed:year |
1994
|
pubmed:articleTitle |
The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, University of Alabama at Birmingham.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Case Reports
|